IL-36 gamma/IL-1F9 Antibody [Alexa Fluor® 594]

• Reactivity: Hu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 594

IL-36 gamma/IL-1F9 Antibody [Alexa Fluor® 594] Summary

• Immunogen: E. coli-derived recombinant human IL‑36 gamma /IL‑1F9 (R&D Systems, Catalog # 2320-IL)
  Met1-Asp169
  Accession # Q9NZH8
• Specificity: Detects human IL‑36 gamma /IL‑1F9 in direct ELISAs and Western blots. In direct ELISAs, approximately 15% cross-reactivity with recombinant human (rh) IL-36 alpha is observed, approximately 5% cross-reactivity with rhIL-37 is observed, and less than 1% cross-re
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Blockade of Receptor-ligand Interaction
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-36 gamma/IL-1F9 Antibody [Alexa Fluor® 594]

• IL-1 epsilon
• IL-1 H1
• IL-1 Related Protein 2
• IL-1(EPSILON)
• IL1E
• IL-1-epsilon
• IL1F9
• IL-1F9
• IL1H1
• IL-1H1
• IL-1-Related Protein 2
• IL1RP2
• IL-1rp2
• IL36 gamma
• IL-36 gamma
• IL36G
• interleukin 1 family, member 9
• interleukin 1-related protein 2
• Interleukin 36, Gamma
• Interleukin-1 epsilon
• interleukin-1 family member 9
• Interleukin-1 homolog 1
• Interleukin-36 Gamma

Background

Human interleukin 1 family member #9 [IL-1F9; also named Interleukin-36 gamma, IL36G, IL-1 epsilon  (epsilon) and IL-1H1] is a member of the IL-1 family, which includes IL-1 beta , IL-1 alpha , IL-1ra, IL-18 and IL-1F5 through F10 (1‑4). All family members show a 12 beta -strand, beta -trefoil configuration, and are believed to have arisen from a common ancestral gene that has undergone multiple duplications (4). IL-1F9 is synthesized as a 19 kDa, 169 amino acid (aa) protein that contains no signal sequence, no prosegment and no potential N-linked glycosylation site (1, 2, 5). The molecule is secreted when transfected into 293-T cells (5). Human to mouse, IL-1F9 has 53% aa sequence identity. Within the family, IL-1F9 shares 30%, 23%, 33%, 57%, 35%, 45%, and 32% aa sequence identity with IL-1 ra, IL-1 beta , IL-1F5, F6, F7, F8, and F10, respectively. Cells reported to express IL-1F9 include Langerhans cells, keratinocytes/stratified squamous epithelium, plus Chief cells and Parietal cells of the stomach (4, 5). The receptor for IL‑1F9 is reported to be a combination of IL-1 Rrp2 and IL-1 RAcP (6). Recombinant IL-1F9, along with IL-1F8 and IL-1F6, has been shown to activate the pathway involving NF-kappa B and MAPK in an IL-1 Rrp2 dependent manner.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q9NZH8()